Detalles de la búsqueda
1.
Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated individuals.
Front Immunol
; 15: 1394114, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38873610
2.
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico.
NPJ Vaccines
; 8(1): 67, 2023 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37164959
3.
Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico.
medRxiv
; 2022 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35169806
4.
Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs.
mBio
; 12(5): e0190821, 2021 10 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34544278
Resultados
1 -
4
de 4
1
Próxima >
>>